# Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60)

> **NCT01819779** · PHASE1 · COMPLETED · sponsor: **Hanlim Pharm. Co., Ltd.** · enrollment: 53 (actual)

## Conditions studied

- Healthy Male Subjects

## Interventions

- **DRUG:** Exforge tab. 10/160mg
- **DRUG:** Lodivixx tab. 5/160mg

## Key facts

- **NCT ID:** NCT01819779
- **Lead sponsor:** Hanlim Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2013-05
- **Final completion:** 2013-11
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2018-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01819779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01819779, "Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01819779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*